Nucleophosmin, Sequencing Exon 12 NPM1 Gene Whole Blood method(s): ◦ Mutation Scanning of Select Exons Reference Laboratory Genetics - Hospitalet de Llobregat, Spain |
Nucleophosmin, Sequencing Exon 12 NPM1 Gene Bone Marrow method(s): ◦ Mutation Scanning of Select Exons Reference Laboratory Genetics - Hospitalet de Llobregat, Spain |
Acute myeloid leukemia (sequence analysis of exon 12 of NPM1 gene) method(s): ◦ Sequencing, Capillary (Sanger) CGC Genetics - Porto, Portugal |
Acute Myeloid Leukemia: Exon 12, NPM1 gene method(s): ◦ Mutation Scanning of Select Exons GENETAQ, Molecular Genetics Centre - Malaga, Spain |
NPM1 Mutation Analysis method(s): ◦ Sequencing, Capillary (Sanger) Diagnostic Labs at BloodCenter of Wisconsin - Milwaukee, WI, USA |
AML Mutation Panel method(s): ◦ Sequencing, Capillary (Sanger) Diagnostic Labs at BloodCenter of Wisconsin - Milwaukee, WI, USA |
AML Mutation Panel - Reflex method(s): ◦ Sequencing, Capillary (Sanger) Diagnostic Labs at BloodCenter of Wisconsin - Milwaukee, WI, USA |
NGS HemeOnc Panel method(s): ◦ Sequencing, Next Gen Diagnostic Labs at BloodCenter of Wisconsin - Milwaukee, WI, USA |
Nucleophosmin (NPM1) Mutation Analysis (exon 12) method(s): ◦ Mutation Scanning of Select Exons Cidegen, SL - Salamanca, Spain |
Targeted Somatic Cancer Panel Sequencing (TSP50) method(s): ◦ Sequencing, Next Gen Genomics for Life APA 1164 - Herston, Queensland, Australia |
Hematopoietic Disorders Gene Set method(s): ◦ Sequencing, Next Gen Genomics and Pathology Services, Washington University - St. Louis, MO, USA |
Somatic Tumor Panel method(s): ◦ Sequencing, Next Gen CeGaT GmbH - Tübingen, Germany |
RT-PCR t(5;17)(q35;q21) NPM/RARA method(s): ◦ Gene Expression Analysis CGC Genetics - Porto, Portugal |
Com.Pl.i.t. DX 54 genes - Comprehensive Panel for Individualized Cancer Threatment method(s): ◦ Del/Dup (CNV) ◦ Multicolor FISH (M-FISH) / Spectral Karotyping (tm) (SKY (tm)) ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen GeneKor Medical S.A. - Athens, Greece |
AML post-FLT3 Comprehensive Mutation Panel method(s): ◦ Sequencing, Capillary (Sanger) Diagnostic Labs at BloodCenter of Wisconsin - Milwaukee, WI, USA |
Hematologic Malignancy Mutation Panel method(s): ◦ Sequencing, Next Gen Baylor Miraca Genetics Laboratories - Houston, TX, USA |
OnkoSight AML Panel method(s): ◦ Sequencing, Next Gen GenPath - Elmwood Park, NJ, USA |
OnkoSight Myeloid Disorders Panel method(s): ◦ Sequencing, Next Gen GenPath - Elmwood Park, NJ, USA |
NPM1 method(s): ◦ Sequencing, Next Gen ◦ Sequencing, Capillary (Sanger) ◦ Del/Dup (CNV) Fulgent Diagnostics - Temple City, CA, USA |
Acute Myeloid Leukemia (Susceptibility to), Panel Massive Sequencing (NGS) 21 Genes method(s): ◦ Sequencing, Next Gen Reference Laboratory Genetics - Hospitalet de Llobregat, Spain |
CEN4GEN Hematological malignancies (somatic genetic testing): Sequencing Panel method(s): ◦ Sequencing, Next Gen CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
CEN4GEN Comprehensive targeted oncogene tumor mutation screen (somatic genetic testing): Sequencing Panel method(s): ◦ Sequencing, Next Gen CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
Cancer Hotspot Panel (somatic mutation analysis) method(s): ◦ Sequencing, Next Gen Centogene AG, Rare Disease Company - Rostock, Germany |